Healthcare
‘I’m not really quite sure’: Fauci can’t answer why Texas isn’t seeing a COVID increase after removing mask mandate
Mainstream media’s favorite doctor doesn’t have an answer for why Texas isn’t seeing an increase in COVID-19 cases several weeks after removing its mask mandate.
“It can be confusing because you may see a lag and a delay,” Fauci said when asked about Texas’ low numbers. “I’m not really quite sure.”
The infectious disease expert floated the idea that cases aren’t popping up because “they’re doing things outdoors.”
He also gave an excuse that it is hard to compare the numbers.
“It’s very difficult to just one-on-one compare that,” he said. “You just have to see the long range.”
Fauci hopes that case continue to tick down but is mindful it may not last.
“I hope they continue to tick down—if they do that would be great,” he said. “But there’s always the concern that when you pull back on methods…you can see a delay and then all the sudden tick right back up.”
And while businesses fail and local economies are in ruins, Fauci said we “gotta be careful…that we don’t prematurely judge that.”
Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.
Foreign Desk News writes:
Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.
“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.
Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.
“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.
The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4
— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023
Foreign Desk News adds:
The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.
-
Economy4 days agoNew York City Mayor Eric Adams Proposes Housing Asylum Seekers in Private Homes
-
Economy5 days agoTexas Gov Abbott aims to eliminate property taxes: ‘we must dream big’
-
Immigration3 days agoBiden Administration to allow 40,000 asylum-seekers per month into US with mobile app
-
International3 days agoSaudi Arabia-Israel Deal Remains Biden’s Win to Lose
